PREVIEW: Johnson & Johnson earnings expected to decline in Q3

Johnson & Johnson

12/10/2026 19:35

** Johnson & Johnson JNJ.N shares up 0.6% at $263.00 on Mon ahead of qtrly results before the bell, with investors watching for a rebound in its medtech unit
** The healthcare conglomerate is expected to post Q3 rev of $25.28 bln and adj EPS of $2.54, down from EPS of $2.80 but up from revenue of $23.99 bln a year ago, per LSEG
** Last qtr, co beat estimates on strong pharma sales but its Abiomed heart pump business saw sales decline following a critical UK study
** In Sept, an experimental depression drug co-developed with Contineum Therapeutics CTNM.O  failed to meet the main goal of a mid-stage study
** JNJ has met or surpassed EPS and revenue estimates for at least past 8 qtrs
** Of the 26 analysts covering Johnson & Johnson, the breakdown of recommendations is 19 "strong buy" or "buy" and 7 "hold" ratings
** Median price target of $282 is unchanged over the past month
** JNJ shares up ~27% YTD, outperforming ~8% gain in Dow Industrials .DJI  

(Reporting by Chuck Mikolajczak)
((charles.mikolajczak@tr.com; @chuckmik.bsky.social))